Valente Manuela 4/A

What Happened

• Manuela Valente, Chief People Officer of SOPHiA GENETICS (SOPH), was granted equity awards on April 2, 2026: 71,869 restricted stock units (RSUs) and 104,790 derivative awards (total 176,659). Both were reported as acquired at $0.00 (typical for compensation grants). Following an amended Form 4, the correct total of ordinary shares she beneficially owns is 224,248 (the original filing misstated this number).

Key Details

• Transaction date: April 2, 2026; Form 4 filed April 8, 2026 as an amendment to the April 3, 2026 filing to correct the ownership amount (see F2).
• Grant amounts and price: 71,869 RSUs @ $0.00; 104,790 derivative awards @ $0.00 (total 176,659 awards).
• Shares beneficially owned after transaction: 224,248 ordinary shares (corrected amount per F2).
• Vesting: RSUs vest 25% on April 2, 2027, then the remaining 75% in equal quarterly installments through April 2, 2030 (F1). The derivative award vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030 (F3).
• Filing note: This is a Form 4/A amending the April 3 filing to correct the amount of shares reported as beneficially owned.

Context

• These are compensation awards (RSUs and a derivative/option-style grant) that vest over multi-year schedules and are contingent on continued service — they do not represent open-market purchases or immediate sales. Until vesting (and, for options, exercise), they have limited liquidity and do not necessarily indicate a near-term trading intent.